Grant Worden

The plaintiff brought a motion to certify a class action against the defendants, alleging that their glyphosate-based herbicide, Roundup, causes non-Hodgkin's lymphoma.

The court analyzed the five certification criteria under the Class Proceedings Act, 1992.

While the court struck the proposed causes of action for battery and unjust enrichment, it found that the pleadings disclosed a valid cause of action in negligence and failure to warn.

The court approved the proposed class definition, certified several common issues including general causation and punitive damages, and concluded that a class proceeding was the preferable procedure.

The action was certified as a class proceeding.

The representative plaintiffs moved to discontinue their Ontario class action regarding allegedly defective surgical staplers, intending to rely instead on an overlapping class action in British Columbia.

The defendants opposed the discontinuance and sought an indefinite adjournment, arguing that discontinuing the Ontario action before the resolution of their stay application in B.C. would prejudice absent class members by restarting the limitation period.

The court agreed that the risk of limitations prejudice to absent class members was too great and adjourned the motion indefinitely.

The court also invoked the Canadian Judicial Protocol for the Management of MultiJurisdictional Class Actions to coordinate with the B.C. court.

The appellants appealed a motion judge's order striking their statement of claim in its entirety without leave to amend, in a product liability action concerning an implanted medical device (Essure).

The Court of Appeal set aside the order, granting leave to amend the statement of claim.

The court clarified that leave to amend should only be denied in the clearest of cases and that, in product liability claims, identifying a specific manufacturing or design defect is not always required at the pleading stage to disclose a cause of action.

The defendants brought a motion on consent to dismiss the putative class action for delay under s. 29.1 of the Class Proceedings Act, 1992.

The action was commenced in 2011 and had been dormant since 2012, with no certification motion record filed or timetable established.

The court found that the mandatory requirements for dismissal under s. 29.1 were met, as the statutory deadline of October 1, 2021, had passed without any required steps being taken.

The action was dismissed, and plaintiffs' counsel was ordered to bear the costs of providing notice of the dismissal.

The plaintiff and remaining defendants in a price-fixing class action sought to certify the action on consent, approve class counsel fees, and dismiss the action.

The class members had previously been compensated through a settlement with other defendants.

The court found no prejudice to the class, certified the action, approved class counsel fees of $239,895.26 from trust funds, and dismissed the action without costs.

The plaintiffs sought certification of a proposed class action against a pharmaceutical manufacturer regarding the oral contraceptives Yasmin and YAZ.

The proposed class included Ontario residents prescribed and using the drugs prior to November 30, 2011, and derivative claimants under the Family Law Act.

The plaintiffs alleged negligence in the design, testing, marketing, and warning associated with the drospirenone component, claiming it posed greater risks than other oral contraceptives.

The court held that the pleadings disclosed viable causes of action, that the proposed class and common issues were sufficiently defined, and that a class proceeding was the preferable procedure under the Class Proceedings Act, 1992.

Certification was granted with certain modifications to the class definition and litigation plan.